ATE367152T1 - Herstellungsverfahren für niedrig dosierte pharmazeutische zusammensetzung - Google Patents

Herstellungsverfahren für niedrig dosierte pharmazeutische zusammensetzung

Info

Publication number
ATE367152T1
ATE367152T1 AT02702671T AT02702671T ATE367152T1 AT E367152 T1 ATE367152 T1 AT E367152T1 AT 02702671 T AT02702671 T AT 02702671T AT 02702671 T AT02702671 T AT 02702671T AT E367152 T1 ATE367152 T1 AT E367152T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
production method
low dose
dose pharmaceutical
low
Prior art date
Application number
AT02702671T
Other languages
English (en)
Inventor
Daniel S Gierer
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE367152T1 publication Critical patent/ATE367152T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02702671T 2001-05-01 2002-03-13 Herstellungsverfahren für niedrig dosierte pharmazeutische zusammensetzung ATE367152T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28784101P 2001-05-01 2001-05-01

Publications (1)

Publication Number Publication Date
ATE367152T1 true ATE367152T1 (de) 2007-08-15

Family

ID=23104578

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02702671T ATE367152T1 (de) 2001-05-01 2002-03-13 Herstellungsverfahren für niedrig dosierte pharmazeutische zusammensetzung

Country Status (44)

Country Link
US (2) US7037530B2 (de)
EP (1) EP1383482B1 (de)
JP (1) JP2004531537A (de)
KR (1) KR100568380B1 (de)
CN (1) CN1240375C (de)
AP (1) AP2003002900A0 (de)
AR (1) AR033288A1 (de)
AT (1) ATE367152T1 (de)
AU (1) AU2002236166B2 (de)
BG (1) BG108297A (de)
BR (1) BR0209283A (de)
CA (1) CA2445519C (de)
CZ (1) CZ20032959A3 (de)
DE (1) DE60221238T2 (de)
DK (1) DK1383482T3 (de)
DO (1) DOP2002000389A (de)
EA (1) EA005949B1 (de)
EC (1) ECSP034826A (de)
EE (1) EE200300537A (de)
ES (1) ES2286226T3 (de)
GE (1) GEP20053654B (de)
GT (1) GT200200078A (de)
HR (1) HRP20030858A2 (de)
HU (1) HUP0401391A3 (de)
IL (1) IL158390A0 (de)
IS (1) IS6985A (de)
MA (1) MA27017A1 (de)
MX (1) MXPA03009391A (de)
NO (1) NO20034709L (de)
NZ (1) NZ528886A (de)
OA (1) OA12596A (de)
PA (1) PA8544401A1 (de)
PE (1) PE20021137A1 (de)
PL (1) PL366453A1 (de)
PT (1) PT1383482E (de)
PY (1) PY0206703A (de)
SK (1) SK286536B6 (de)
TN (1) TNSN03106A1 (de)
TW (1) TWI264311B (de)
UA (1) UA75135C2 (de)
UY (1) UY27277A1 (de)
WO (1) WO2002087546A2 (de)
YU (1) YU81503A (de)
ZA (1) ZA200307819B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2479924C (en) 2002-03-28 2008-07-15 Pfizer Products Inc. Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization
PA8576201A1 (es) 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
US7444197B2 (en) 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
US7799273B2 (en) 2004-05-06 2010-09-21 Smp Logic Systems Llc Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes
WO2008143607A1 (en) * 2006-05-17 2008-11-27 Wm. Wrigley Jr. Company Method of preparing a food product
US8951562B2 (en) 2006-11-10 2015-02-10 Atacama Labs Oy Method and apparatus or dry granulation
FI20070521A7 (fi) 2006-11-10 2008-05-11 Atacama Labs Oy Rakeita, tabletteja ja rakeistusmenetelmä
FI20080351A0 (fi) * 2008-05-09 2008-05-09 Atacama Labs Oy Prosessi matalan lääkepitoisuuden tabletin valmistamiseksi
US20100179110A1 (en) * 2006-12-20 2010-07-15 Mostafa Akbarieh Composition Containing a Bisphosphonic Acid in Combination with Vitamin D
US20080181972A1 (en) * 2007-01-29 2008-07-31 Valentina Amico Compositions and Methods for Maintaining, Strengthening, Improving, or Promoting Eye Health
PT3150586T (pt) 2007-02-23 2020-03-31 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
EA201591353A1 (ru) 2008-05-02 2016-01-29 Джилид Сайэнс, Инк. Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента
WO2009135946A1 (en) * 2008-05-09 2009-11-12 Atacama Labs Oy Method and apparatus for dry granulation
PL2299987T3 (pl) * 2008-06-06 2018-08-31 Boehringer Ingelheim International Gmbh Farmaceutyczna postać dawkowania w formie kapsułki zawierająca formulację zwiesiny pochodnej indolinonu
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
AU2010209790B2 (en) * 2009-01-29 2014-01-16 Ucb Pharma, S.A. Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
KR101640164B1 (ko) * 2009-01-29 2016-07-15 유씨비 파마, 에스.에이. ２­옥소­１­피롤리딘 유도체를 포함하는 약학적 조성물
US20140350945A1 (en) * 2013-05-22 2014-11-27 Professional Compounding Centers Of America System and Method for Validation of Pharmaceutical Composition Formulations
CN103830196A (zh) * 2014-03-14 2014-06-04 王志刚 一种酒石酸拉索昔芬分散片及其制备方法
CN106176649B (zh) * 2016-08-31 2020-04-17 北京斯利安药业有限公司 叶酸vb12片及其制备方法
MX2019009777A (es) * 2017-02-17 2019-10-14 Massachusetts Inst Technology Sistemas y metodos para la fabricacion de tabletas, que incluyen tabletas farmaceuticas.
CZ309820B6 (cs) * 2021-04-23 2023-11-08 Pro.Med.Cs Praha A.S. Způsob přípravy pevné lékové formy obsahující kompozici s nízkým obsahem účinné látky
CN117530926A (zh) 2022-08-02 2024-02-09 江苏众红生物工程创药研究院有限公司 一种舌下片及其在脱敏治疗药物中的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3725555A (en) * 1967-08-01 1973-04-03 Ciba Geigy Corp Bactericidal compositions and method of killing bacteria using bis-(phenoxyphenyl) carbonates
US3725556A (en) * 1970-11-12 1973-04-03 D Hanssen Method of manufacturing rapidly disintegrating pharmaceutical tablets
US4013785A (en) * 1975-03-21 1977-03-22 Bristol-Myers Company Apap tablet containing fumed silica and process for manufacturing same
GB1570993A (en) * 1976-05-21 1980-07-09 Fisons Ltd Pharmaceutical tablet formulation
DE2845326C2 (de) * 1978-10-18 1985-05-23 Beiersdorf Ag, 2000 Hamburg Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung
US4489026A (en) * 1982-09-07 1984-12-18 The Upjohn Company Process for preparing solid unit dosage forms of ultra-low dose drugs
US5004613A (en) * 1987-07-27 1991-04-02 Mcneil-Ppc, Inc. Oral sustained release pharmaceutical formulation and process
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
US5107331A (en) * 1989-03-07 1992-04-21 The Color Group Method and apparatus for producing half-tone separations at the same screen angle
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
IE67345B1 (en) * 1991-03-12 1996-03-20 Akzo Nv Low dose dry pharmaceutical preparations
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
US5928668A (en) * 1993-12-21 1999-07-27 Applied Analytical Industries, Inc. Method for dry blend compression of medicaments
US5976570A (en) * 1993-12-21 1999-11-02 Applied Analytical Industries, Inc. Method for preparing low dose pharmaceutical products
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
US5726168A (en) * 1995-10-12 1998-03-10 Eli Lilly And Company Lipophilic benzothiophenes
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
US5733578A (en) * 1995-11-15 1998-03-31 Edward Mendell Co., Inc. Directly compressible high load acetaminophen formulations
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US5916916A (en) * 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
JPH10204082A (ja) * 1996-10-25 1998-08-04 Eli Lilly & Co 選択的エストロゲンレセプターモジュレーターとしての活性を有する置換されたベンゾ［ｂ］チオフェン化合物
US6080427A (en) * 1997-04-17 2000-06-27 Bristol-Myers Squibb Company Cefadroxil monohydrate tablet formulation
ES2257795T3 (es) * 1997-07-01 2006-08-01 Pfizer Products Inc. Procedimiento para producir una ciclodextrina.
US6300367B1 (en) * 1999-04-20 2001-10-09 Protein Technologies International, Inc. Composition for and method of preventing or treating breast cancer
US6555551B1 (en) * 1999-08-31 2003-04-29 Mutual Pharmaceutical Co., Inc. Stable formulations of ACE inhibitors, and methods for preparation thereof
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos

Also Published As

Publication number Publication date
KR100568380B1 (ko) 2006-04-05
UA75135C2 (en) 2006-03-15
PY0206703A (es) 2004-07-01
DE60221238T2 (de) 2007-10-31
WO2002087546A3 (en) 2003-02-13
AP2003002900A0 (en) 2003-12-31
PL366453A1 (pl) 2005-02-07
IS6985A (is) 2003-10-09
BR0209283A (pt) 2004-07-13
EP1383482A2 (de) 2004-01-28
CZ20032959A3 (cs) 2004-01-14
IL158390A0 (en) 2004-05-12
EE200300537A (et) 2004-04-15
UY27277A1 (es) 2002-11-29
PT1383482E (pt) 2007-09-20
EA200301040A1 (ru) 2004-04-29
HRP20030858A2 (en) 2005-08-31
KR20040015226A (ko) 2004-02-18
OA12596A (en) 2006-06-08
DOP2002000389A (es) 2002-11-30
US7176221B2 (en) 2007-02-13
ES2286226T3 (es) 2007-12-01
CA2445519C (en) 2009-01-20
US20030004182A1 (en) 2003-01-02
SK13552003A3 (sk) 2004-09-08
US7037530B2 (en) 2006-05-02
HUP0401391A2 (hu) 2004-12-28
NZ528886A (en) 2005-04-29
ZA200307819B (en) 2004-10-07
BG108297A (bg) 2005-07-29
SK286536B6 (sk) 2008-12-05
PE20021137A1 (es) 2002-12-14
YU81503A (sh) 2006-08-17
TNSN03106A1 (fr) 2005-12-23
JP2004531537A (ja) 2004-10-14
HUP0401391A3 (en) 2009-06-29
CN1531423A (zh) 2004-09-22
DE60221238D1 (de) 2007-08-30
CA2445519A1 (en) 2002-11-07
EA005949B1 (ru) 2005-08-25
PA8544401A1 (es) 2003-07-28
US20060093667A1 (en) 2006-05-04
WO2002087546A2 (en) 2002-11-07
TWI264311B (en) 2006-10-21
HK1065705A1 (en) 2005-03-04
MXPA03009391A (es) 2004-01-29
DK1383482T3 (da) 2007-10-29
AR033288A1 (es) 2003-12-10
AU2002236166B2 (en) 2006-12-07
NO20034709L (no) 2003-10-31
GT200200078A (es) 2003-01-31
CN1240375C (zh) 2006-02-08
MA27017A1 (fr) 2004-12-20
EP1383482B1 (de) 2007-07-18
ECSP034826A (es) 2004-02-26
GEP20053654B (en) 2005-11-10
NO20034709D0 (no) 2003-10-21

Similar Documents

Publication Publication Date Title
FI20011478L (fi) Farmaseuttinen koostumus
NO20033815L (no) Farmasöytiske salter
EP1603593A4 (de) Pharmazeutische zusammensetzung
PL367180A1 (pl) Trwała kompozycja farmaceutyczna
EE200300416A (et) Ravimvorm
DK2092935T3 (da) Farmaceutiske sammensætninger til behandling astma
EE200300369A (et) Atsüülitud indanüülamiinid, nende valmistamismeetod, kasutamine ja farmatseutiline preparaat
DK1524266T3 (da) Farmaceutisk sammensætning
EE200300537A (et) Meetod madalaannuselise farmatseutilise kompositsiooni tootmiseks
EP1425019A4 (de) Pharmazeutische zusammensetzung
PT1467724E (pt) Composicao farmaceutica orodispersavel de agomelatina
DK1587478T3 (da) Farmaceutisk sammensætning
NO20033042D0 (no) Cyklodekstrin-inneholdende farmasöytisk preparat
EE200300589A (et) Ravimkoostised
FI20022128L (fi) Farmaseuttinen koostumus
DE60211183D1 (de) Pharmazeutische zusammensetzung enthaltend lumiracoxib
EP1408896A4 (de) Pharmazeutische zusammensetzung
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
NO20034556L (no) Imidazotriazinon-holdige sammensetninger for nasal administrering
PT1603550E (pt) Composição farmacêutica que compreende ácido 5-metil-2-2¿- (cloro-6¿-fluoroanilino)fenilacético
ATE248171T1 (de) Isoindoloindolon-derivate, verfahren zu ihrer herstellung und die enthaltende pharmazeutische zusammensetzungen
DE10291905D2 (de) Pharmazeutische Zusammensetzung
ATE350029T1 (de) Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
IS7581A (is) Lyfjasamsetning
FI20012242A0 (fi) Uudet farmaseuttiset yhdisteet

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1383482

Country of ref document: EP

REN Ceased due to non-payment of the annual fee